News
MNMD
8.52
+0.71%
0.06
This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even Higher
NASDAQ · 14h ago
Weekly Report: what happened at MNMD last week (0415-0419)?
Weekly Report · 3d ago
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Benzinga's psychedelic headlines roundup includes a look at the first two weeks of April 2024. Psilocybin could alter mechanisms associated with major depression and neurodegenerative diseases. Ancient Romans used to trip on hallucinogenic plants, archeologists say. Psycon's 2024 edition will take place in Colorado in May.
Benzinga · 04/17 13:13
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist on Hearings. The Drug Enforcement Administration is revisiting its stance on the classification of two psychedelic compounds. The agency has proposed both be listed as Schedule I substances with no recognized medical use. Benzinga Psychedelics Podcast features an expert on the ancient healing plant kanna.
Benzinga · 04/17 12:42
Leerink Partners Initiates Coverage of Mind Medicine (MNMD) with Outperform Recommendation
NASDAQ · 04/15 23:01
Leerink Partners Initiates Coverage On Mind Medicine with Outperform Rating, Announces Price Target of $20
Benzinga · 04/15 14:30
Weekly Report: what happened at MNMD last week (0408-0412)?
Weekly Report · 04/15 10:47
MIND MEDICINE (MINDMED) INC <MNMD.O>: LEERINK PARTNERS INITIATES COVERAGE WITH OUTPERFORM RATING AND $20 PRICE TARGET
Reuters · 04/15 10:17
Roblox, TAL Education And Other Big Stocks Moving Higher On Wednesday
Shares of Roblox Corporation (RBLX) rose 2.6% to $40.10 on Wednesday. Dow Jones index fell over 300 points in Wednesday’s session. The company has ramped up efforts to attract advertisers to its platform. U.S. Stocks were lower on the day.
Benzinga · 04/10 14:56
MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why
NASDAQ · 04/08 10:59
Weekly Report: what happened at MNMD last week (0401-0405)?
Weekly Report · 04/08 10:52
Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
Seeking Alpha · 04/04 16:43
Simulations Plus Posts Upbeat, Joins Levi Strauss, BlackBerry And Other Big Stocks Moving Higher In Thursday's Pre-Market Session
Shares of Simulations Plus, Inc. Rose sharply in today’s pre-market trading after the company posted better-than-expected results for its second quarter. The Dow futures were higher by around 90 points on Thursday morning. Destiny Tech100 Inc. And Cronos Group also recorded gains in today's pre- market trading.
Benzinga · 04/04 09:18
Mind Medicine Inc. Statement Inaccessible
TipRanks · 04/01 23:37
MindMed to voluntarily delist from CBOE Canada
Healthcare MindMed to voluntarily delist from CBOE Canada on April 10, 2024. MindMed’s common shares will continue to be listed and tradable on The Nasdaq Global Select Market under the symbol ‘MNMD’ The Company believes the trading volume of its common shares on Cboe Canada no longer justifies the dual listing.
Seeking Alpha · 04/01 21:10
MIND MEDICINE (MINDMED) INC: ELECTED TO VOLUNTARILY DELIST ITS COMMON SHARES FROM CBOE CANADA, EFFECTIVE AT CLOSE OF MARKETS ON APRIL 10
Reuters · 04/01 21:00
MindMed Announces Voluntary Delisting from Cboe Canada
MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. The Company has elected to voluntarily delist its common shares from Cboe Canada effective April 10, 2024. MindMed’s common shares will continue to be listed and tradable on The Nasdaq Global Select Market.
Barchart · 04/01 16:00
Weekly Report: what happened at MNMD last week (0325-0329)?
Weekly Report · 04/01 10:49
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Utah hospitals will soon provide psilocybin and MDMA therapy for mental health conditions in a pilot program. Beckley Psytech and atai announce positive initial results from a clinical trial of 5-MeO-DMT in Treatment Resistant Depression. Prosecutors in Virginia are probing whether Facebook's social media platforms are facilitating the illegal sale of drugs. Elon Musk makes the case for using psychedelics in a new episode of the Benzinga Psychedelics Podcast.
Benzinga · 03/29 16:43
Mind Medicine (NASDAQ:MNMD) is Leading the Surge in Psychedelic Therapies
TipRanks · 03/27 08:49
More
Webull provides a variety of real-time MNMD stock news. You can receive the latest news about Mind Medicine through multiple platforms. This information may help you make smarter investment decisions.
About MNMD
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).